Michael Gelband ExodusPoint Capital Management
Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$353M |
| 2 |
Microsoft
MSFT
|
+$352M |
| 3 |
Apple
AAPL
|
+$256M |
| 4 |
Alibaba
BABA
|
+$189M |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$125M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SCHW
Charles Schwab
SCHW
|
+$82M |
| 2 |
Generac Holdings
GNRC
|
+$33.7M |
| 3 |
Pool Corp
POOL
|
+$32.5M |
| 4 |
Keurig Dr Pepper
KDP
|
+$31M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$25M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.28% |
| 2 | Consumer Discretionary | 10.77% |
| 3 | Healthcare | 5.09% |
| 4 | Industrials | 4.03% |
| 5 | Financials | 3.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1726
G-III Apparel Group
GIII
$1.43B
| $202K | ﹤0.01% |
8,504
-17,432
| -67% | -$324K |
|
1727
Ichor Holdings
ICHR
$2.13B
| $202K | ﹤0.01% |
+6,704
| New | +$190K |
|
1728
Intercorp Financial Services
IFS
$6.06B
| $202K | ﹤0.01% |
+6,237
| New | +$162K |
|
1729
Knowles
KN
$2.77B
| $202K | ﹤0.01% |
10,960
-4,706
| -30% | -$78.7K |
|
|
SURF
1730
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $202K | ﹤0.01% |
+21,907
| New | +$190K |
|
1731
Shinhan Financial Group
SHG
$35.2B
| $201K | ﹤0.01% |
6,739
-21,262
| -76% | -$607K |
|
1732
Travere Therapeutics
TVTX
$6.09B
| $201K | ﹤0.01% |
+7,372
| New | +$172K |
|
1733
National Beverage
FIZZ
$3.1B
| $200K | ﹤0.01% |
+4,722
| New | +$203K |
|
|
HIMX
1734
Himax Technologies
HIMX
$2.33B
| $199K | ﹤0.01% |
+26,981
| New | +$138K |
|
|
RDUS
1735
DELISTED
Radius Health, Inc.
RDUS
| $199K | ﹤0.01% |
11,131
-2,889
| -21% | -$43.4K |
|
1736
Equinox Gold
EQX
$15.9B
| $198K | ﹤0.01% |
+19,136
| New | +$209K |
|
1737
Evolent Health
EVH
$528M
| $197K | ﹤0.01% |
12,290
-11,404
| -48% | -$151K |
|
1738
CorMedix
CRMD
$658M
| $195K | ﹤0.01% |
+26,229
| New | +$178K |
|
1739
Lincoln Educational Services
LINC
$820M
| $195K | ﹤0.01% |
+30,003
| New | +$178K |
|
1740
Altimmune
ALT
$599M
| $194K | ﹤0.01% |
+17,213
| New | +$203K |
|
1741
KT
KT
$9.01B
| $194K | ﹤0.01% |
+17,652
| New | +$186K |
|
|
TEF
1742
DELISTED
Telefonica
TEF
| $193K | ﹤0.01% |
+53,786
| New | +$182K |
|
|
CODX
1743
Co-Diagnostics
CODX
$7.63M
| $192K | ﹤0.01% |
690
+277
| +67% | +$103K |
|
1744
Harmonic Inc
HLIT
$1.32B
| $192K | ﹤0.01% |
+26,000
| New | +$171K |
|
|
BFI
1745
DELISTED
BurgerFi International, Inc. Common Stock
BFI
| $192K | ﹤0.01% |
+14,060
| New | +$177K |
|
|
MNRL
1746
DELISTED
Brigham Minerals, Inc. Class A Common Stock
MNRL
| $191K | ﹤0.01% |
17,424
-19,302
| -53% | -$199K |
|
1747
ADMA Biologics
ADMA
$2.19B
| $190K | ﹤0.01% |
+97,656
| New | +$205K |
|
1748
Petrobras Class A
PBR.A
$107B
| $190K | ﹤0.01% |
+17,135
| New | +$150K |
|
1749
Prothena Corp
PRTA
$474M
| $188K | ﹤0.01% |
15,692
-7,808
| -33% | -$92.3K |
|
|
TIO
1750
DELISTED
Tingo Group, Inc. Common Stock
TIO
| $187K | ﹤0.01% |
+90,065
| New | +$200K |
|
Similar funds
Michael Gelband's Q4 2020 Portfolio in Review
As of Q4 2020, Michael Gelband held 2,600 positions worth $10.3B, up 105% from $5.02B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Michael Gelband deployed $4.62B of net new capital in Q4 2020, opening 918 new positions and adding to 493 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 352,707 shares worth $132M.
By sector, the portfolio is most concentrated in Technology at 14% of assets, up from 11% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was Charles Schwab, an estimated $82M trimmed.
- Michael Gelband's largest Q4 2020 buy was State Street SPDR S&P 500 ETF Trust: 352,707 shares worth $132M.
- Michael Gelband added most to Amazon in Q4 2020, an estimated $353M increase.
- Michael Gelband's biggest Q4 2020 reduction was Charles Schwab, cutting an estimated $82M.
- Michael Gelband fully exited Eli Lilly in Q4 2020, selling an estimated $21.7M.
- Michael Gelband's ten largest holdings make up 42% of its $10.3B portfolio in Q4 2020.
- Michael Gelband opened 918 new positions and closed 701 in Q4 2020.
- Michael Gelband's portfolio value rose 105% quarter-over-quarter to $10.3B.
Based on ExodusPoint Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.